Bristol Myers Squibb Company (NYSE:BMY) Given Average Recommendation of “Hold” by Brokerages

Shares of Bristol Myers Squibb Company (NYSE:BMY) have been given a consensus recommendation of “Hold” by the twenty-one analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $56.8571.

A number of research analysts have recently commented on BMY shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. HSBC reaffirmed a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Morgan Stanley reaffirmed an “underweight” rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. Finally, Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of hedge funds have recently modified their holdings of the stock. Trifecta Capital Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth $25,000. Harbor Capital Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares during the last quarter. REAP Financial Group LLC increased its holdings in shares of Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at approximately $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Down 2.3%

Shares of NYSE:BMY opened at $55.30 on Friday. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The company has a market cap of $112.58 billion, a PE ratio of 18.68, a P/E/G ratio of 9.15 and a beta of 0.29. The company’s 50-day moving average price is $51.91 and its 200 day moving average price is $48.13.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter in the previous year, the company posted $1.80 earnings per share. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 85.14%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.